Catalog No.
RHG62601
Species reactivity
Human, Mouse, Rat
Host species
Rabbit
Isotype
IgG
Clonality
Monoclonal
Tested applications
IP: 1:20-1:50, WB: 1:1000-1:2000
Target
5T4, 5T4AG, M6P1, TPBG, 5T4 oncofetal antigen, Trophoblast glycoprotein, Trophoblast glycoprotein
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q13641
Applications
IP, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Store at +4 ℃ short term (1-2 weeks).
Store at -20 ℃ 12 months.
Store at -80 ℃ long term.
Clone ID
R1B30
Identification and validation of a novel autoantibody biomarker panel for differential diagnosis of pancreatic ductal adenocarcinoma., PMID:39949781
Immunohistochemical Detection of 5T4 in Renal Cell Carcinoma., PMID:36735485
Identification of TPBG-Expressing Amacrine Cells in DAT-tdTomato Mouse., PMID:35551574
ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models., PMID:34045226
Expression and distribution of trophoblast glycoprotein in the mouse retina., PMID:31891182
Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma., PMID:31686124
Identification of PKCα-dependent phosphoproteins in mouse retina., PMID:31255707
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer., PMID:30736848
Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition., PMID:30352801
Expression of 5T4 extracellular domain fusion protein and preparation of anti-5T4 monoclonal antibody with high affinity and internalization efficiency., PMID:29981846
The breast cancer antigen 5T4 interacts with Rab11, and is a target and regulator of Rab11 mediated trafficking., PMID:29549047
5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy., PMID:28537896
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors., PMID:28070718
5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma., PMID:27780858
5T4 oncofoetal antigen: an attractive target for immune intervention in cancer., PMID:27757559
Biodistribution and Targeting of Anti-5T4 Antibody-Drug Conjugate Using Fluorescence Molecular Tomography., PMID:27466353
Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes., PMID:26319086
Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice., PMID:26180901
Trophoblast glycoprotein promotes pancreatic ductal adenocarcinoma cell metastasis through Wnt/planar cell polarity signaling., PMID:25738465
Evolving Strategies for Target Selection for Antibody-Drug Conjugates., PMID:25585957
TroVax in colorectal cancer., PMID:25483641
Phenotype of TPBG Gene Replacement in the Mouse and Impact on the Pharmacokinetics of an Antibody-Drug Conjugate., PMID:25423493
Understanding and exploiting 5T4 oncofoetal glycoprotein expression., PMID:25066861
A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugate., PMID:24578215
The tumor targeted superantigen ABR-217620 selectively engages TRBV7-9 and exploits TCR-pMHC affinity mimicry in mediating T cell cytotoxicity., PMID:24194959
Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4., PMID:23603858
Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells., PMID:23223830
Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy., PMID:22127365
Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells., PMID:21540235
Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells., PMID:21056008
Trophoblast glycoprotein: possible candidate mediating podocyte injuries in glomerulonephritis., PMID:20980737
Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients., PMID:20948436
Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity., PMID:20463598
CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells., PMID:20376365
5T4 as a target for immunotherapy in renal cell carcinoma., PMID:19954280
Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma., PMID:19128501
Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial., PMID:19010868
Epithelial-mesenchymal transition events during human embryonic stem cell differentiation., PMID:18056451
Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses., PMID:17671134
E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cells., PMID:17507657
5T4 oncotrophoblast glycoprotein: janus molecule in life and a novel potential target against tumors., PMID:17484803
Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated., PMID:16311730
Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy., PMID:16222313
Viral vectors for cancer immunotherapy., PMID:16146772
Embryonic expression of murine 5T4 oncofoetal antigen is associated with morphogenetic events at implantation and in developing epithelia., PMID:15977177
The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens., PMID:15838376
In vivo evaluation of an EIAV vector for the systemic genetic delivery of therapeutic antibodies., PMID:15772687
Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors., PMID:12481437
Oncofetal antigen 5T4 expression as a prognostic factor in patients with gastric cancer., PMID:12168897
Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancer., PMID:12003637
For research use only. Not for human or drug use.
